CAMBRIDGE, Mass., Sept. 8 /PRNewswire-FirstCall/ -- Verenium Corporation , a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced that the previously announced 1-for-12 reverse stock split of the Company's common stock will take effect after market close on Wednesday, September 9, 2009. Verenium's shares will continue to trade on the NASDAQ Global Market under the symbol VRNM. A new CUSIP number will be assigned to Verenium's common stock when the split becomes effective.
Verenium's transfer agent, American Stock Transfer, is the exchange agent for the reverse split and will distribute a letter of transmittal to record holders with instructions for the surrender of old stock certificates. For beneficial holders of pre-reverse split shares, the brokerage firm where the beneficial shares are held will make the appropriate adjustment to the number of shares held following the effective date of the reverse split.
Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions. For more information on Verenium, visit http://www.verenium.com.
Verenium Contacts:
SOURCE Verenium Corporation
CONTACT: Kelly Lindenboom, Vice President, Corporate Communications,
+1-617-674-5335, kelly.lindenboom@verenium.com, or Sarah Carmody, Sr.
Corporate Communications Associate, +1-617-674-5357,
sarah.carmody@verenium.com, both of Verenium Corporation
Web site: http://www.verenium.com/
